CURRENT ISSUE
November, 2026
No. 111 (11)
2025 Impact Factor: 8.2
2025 Journal Citation Indicator: 1.77
2025 CiteScore: 9.7
2025 Journal Citation Indicator: 1.77
2025 CiteScore: 9.7
EDITOR'S PICKS
Review Article
Prognosis in marginal zone lymphoma: a comprehensive review
ARTICLES IN THREE SENTENCES
Letter
Novel KAT6B::NUTM2B fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy
Congenital acute myeloid leukemia (AML) is rare and can harbor gene fusions that drive leukemogenesis through aberrant HOXA gene activation. Voss and colleagues identified a novel KAT6B::NUTM2B fusion in an infant with AML and investigated its oncogenic properties and sensitivity to men in inhibition in vitro. Menin inhibition suppressed leukemic cell growth, reduced HOXA9/10 expression and promoted myeloid differentiation.
Article
Immune evasion in primary central nervous system lymphoma: macrophage and T cell roles in response to immunotherapy
Primary central nervous system lymphoma (PCNSL) evades immune surveillance, limiting the efficacy of immunotherapy in this aggressive disease. Using a syngeneic mouse model, Pagès-Geli and colleagues investigated how macrophages, microglia and tumor MHC class I expression shape responses to PD-1 blockade. Myeloid cells supported antitumor immunity, with MHC class I expression influencing treatment response.
Article
Cyp7b1-inhibiting azoles enhance hematopoietic stem and progenitor cell mobilization in normal and sickle cell disease mice
Mobilizing hematopoietic stem and progenitor cells (HSPC) remains challenging in sickle cell disease (SCD), in which granulocyte colony-stimulating factor can trigger life-threatening vaso-occlusive crises. Vu and colleagues investigated in mouse models whether inhibiting Cyp7b1, the enzyme that metabolizes 27-hydroxycholesterol, could enhance HSPC mobilization. Cyp7b1-inhibiting azoles enhanced AMD3100-induced mobilization in normal and SCD mice, suggesting a potential strategy to improve HSPC collection for gene therapy.
Article
Establishing reverse chimeric antigen receptor T cells for precise targeting of immune-mediated thrombotic thrombocytopenic purpura
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) can relapse despite current therapies, highlighting the need to eliminate disease-causing autoreactive B cells. Gupte and colleagues developed reverse chimeric antigen receptor (RevCAR) T cells and adapter modules to target either CD19+ B cells or anti-ADAMTS13 autoreactive B cells. The platform selectively eliminated target cells in vitro, providing proof of concept for a more precise approach.
TAKE ADVANTAGE FROM HAEMATOLOGICA
